Evidence map›Paper›PMID 12037070›Full record

Trial reportJournal of clinical microbiology2002

Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter.

Lisa M Demeter, Ronald J Bosch, Robert W Coombs, Susan Fiscus, James Bremer, Victoria A Johnson, Alejo Erice, J Brooks Jackson, Stephen A Spector, Kathleen M Squires and 3 more

Registry-linked trialOpen access · greenAbstract readClinical TrialClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in Journal of clinical microbiology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00000841 (A Randomized, Double-Blind, Phase III Study of Indinavir Sulfate With Open-Label Zidovudine), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000841 phase3completednot on this map

A Randomized, Double-Blind, Phase III Study of Indinavir Sulfate With Open-Label Zidovudine (AZT) and Lamivudine (3TC) in Subjects With HIV Infection With CD4 Cell Counts <= 200 Cells/mm3 and >= 6 Months of Prior AZT Experience

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrolled1,750ConditionsHIV InfectionsArmsIndinavir sulfate, Lamivudine, Stavudine, Zidovudine
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Lisa M DemeterUniversity of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA. Lisa_Demeter@urmc.rochester.edu
Ronald J Bosch
Robert W Coombs
Susan Fiscus
James Bremer
Victoria A Johnson
Alejo Erice
J Brooks Jackson
Stephen A Spector
Kathleen M Squires
Margaret A Fischl
Michael D Hughes
Scott M Hammer
University of Rochester · USUniversity of Alabama at Birmingham · USColumbia University · USJohns Hopkins University · USUniversity of California, San Diego · USUniversity of Miami · USUniversity of Minnesota System · USUniversity of North Carolina at Chapel Hill · USUniversity of Washington · US

Funding

WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
STATISTICAL AND DATA MANAGEMENT CENTERU01AI038855 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUGHES, MICHAEL DAVID · 1996 to 2006
$78.1M
THE PERINATAL COMPLICATIONS OF ASYMPTOMATIC GENITAL HERPES SIMPLEX VIRUSP01AI030731 · NIAID · UNIVERSITY OF WASHINGTON · PI JOHNSTON, CHRISTINE MICHELLE · 1991 to 2017
$34.3M
YOHIMBINE CHALLENGE IN PARKINSONIAN PATIENTS WITH PANIC DISORDERM01RR000044 · NCRR · UNIVERSITY OF ROCHESTER · PI GUZICK, DAVID S · 1985 to 2006
$13.8M
WOMEN'S HEALTH AGENDAU01AI027658 · NIAID · UNIVERSITY OF ROCHESTER · PI REICHMAN, RICHARD C. · 1988 to 2006
$13.4M
WOMEN'S HEALTH AGENDAU01AI027664 · NIAID · UNIVERSITY OF WASHINGTON · PI COLLIER, ANN CORNWALL · 1988 to 2006
$11.4M
SUSTAINED HIV1 SUPPRESSION DESPITE DRUG RESISTANCER01AI040876 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI JOHNSON, VICTORIA A · 1997 to 2000
$226k
NCRR NIH HHS M01 RR000044NCRR NIH HHS RR-00044NIAID NIH HHS AI-27658NIAID NIH HHS AI-27664NIAID NIH HHS AI-30731NIAID NIH HHS AI-38855NIAID NIH HHS AI-38858NIAID NIH HHS AI-40876NIAID NIH HHS P01 AI030731NIAID NIH HHS U01 AI027658NIAID NIH HHS U01 AI027664NIAID NIH HHS U01 AI038855NIAID NIH HHS U01 AI038858Wellcome Trust
6 · The paper itself

Abstract

We determined the frequency with which human immunodeficiency virus (HIV) peripheral blood mononuclear cell cultures convert from positive to negative in subjects enrolled in a substudy of AIDS Clinical Trials Group (ACTG) 320, which compared the efficacy of treatment with a combination of indinavir, zidovudine, and lamivudine (indinavir arm) to that of a combination of zidovudine and lamivudine (dual-nucleoside arm). All subjects included for study had positive baseline HIV cultures. Cultures were performed in real time with 10(7) fresh patient peripheral blood mononuclear cells, using the ACTG consensus method. We found lower rates of positive HIV cultures in the indinavir treatment arm than in the dual-nucleoside treatment arm (64 versus 96% at week 24, P < 0.001). Within the indinavir arm of the study, we found that positive cultures were less likely to occur in samples with a plasma HIV type 1 (HIV-1) RNA level of <500 copies/ml than in those with a level of >or=500 copies/ml (44 versus 90%, P < 0.001). In addition, HIV cultures from samples with HIV-1 RNA levels of >or=500 copies/ml turned positive 8.5 days earlier, on average, than those from samples with levels of <500 copies/ml (P < 0.001). However, 38% of samples with plasma RNA levels of <50 copies/ml still were positive for HIV by culture. Thus, the rates of HIV isolation by standard culture procedures decrease as the plasma viral load decreases below 1,000 copies/ml; however, HIV isolates were still obtained from a substantial proportion of subjects with RNA levels of <50 copies/ml. The delay in the time required for HIV cultures to turn positive should be considered when attempting to obtain an HIV isolate from patients with suppression of plasma viral load.

Indexed as

Virus ReplicationAdultAnti-HIV AgentsCells, CulturedDrug Therapy, CombinationFemaleHIV-1HIV InfectionsHumansLeukocytes, MononuclearMalePredictive Value of TestsReverse Transcriptase InhibitorsRNA, ViralViral LoadAnti-HIV AgentsReverse Transcriptase InhibitorsRNA, Viral

Identifiers

PMID12037070
PMCPMC130703
OpenAlexW2119712360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.